BackMyMD Pharmaceuticals Overview

MyMD Pharmaceuticals Total Liabilities

Track MyMD Pharmaceuticals's total liabilities ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$0.00
100.00% YoYΔ $-4.94M vs prior year quarter

Peer average

Loading

MyMD Pharmaceuticals Total Liabilities History

Loading

MyMD Pharmaceuticals vs. peers: Total Liabilities Comparison

Loading

MyMD Pharmaceuticals Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

MyMD Pharmaceuticals (MYMD) FAQ

MyMD Pharmaceuticals's total liabilities stands at $0 as of March 2026. That compares with $4.9M in the prior-year period — down 100.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

MyMD Pharmaceuticals reported $0 in total liabilities versus $4.9M a year earlier — a 100.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $4.9M in the prior-year period — down 100.0% year over year. Sustained growth in total liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how MyMD Pharmaceuticals's total liabilities evolved across reporting periods, while the comparison chart places MYMD next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total liabilities is commonly used to spot outliers. MyMD Pharmaceuticals's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.